Search tips
Search criteria 


Logo of jcinvestThe Journal of Clinical InvestigationCurrent IssueArchiveSubscriptionAbout the Journal
J Clin Invest. 1992 June; 89(6): 1923–1930.
PMCID: PMC295892

Vertical transmission of human immunodeficiency virus (HIV) infection. Reactivity of maternal sera with glycoprotein 120 and 41 peptides from HIV type 1.


The observation that approximately 70% of HIV-infected pregnant women do not transmit infection vertically suggests that antibody therapy may be effective in the prevention of transmission of HIV infection from mother to child. Currently, there is an incomplete understanding of the processes involved in vertical transmission of HIV infection. The elucidation of the serological basis of maternal immunity as it relates to protection from vertical transmission is the goal of this study. We have screened 20 maternal sera from HIV+ individuals of known vertical transmission status for reactivity with 31 peptides spanning the entire envelope glycoprotein of HIV-1. Of interest was reactivity to regions outside of the V3 loop of gp120. The findings have been examined in relationship to transmission status, as well as to in vitro anti-HIV-1 biological activity. Our results indicate that lack of vertical transmission is correlated with high viral neutralization activity, but not with antisyncytial activity nor with binding to the V3 peptides examined in this study. Also, the transmission group bound to fewer gp41 peptides when compared with the nontransmission group, suggesting that immune responses to gp41 may be important in preventing transmission. These findings may provide insights into the design of passive immunotherapies.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (1.3M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Barré-Sinoussi F, Chermann JC, Rey F, Nugeyre MT, Chamaret S, Gruest J, Dauguet C, Axler-Blin C, Vézinet-Brun F, Rouzioux C, et al. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science. 1983 May 20;220(4599):868–871. [PubMed]
  • Gallo RC, Sarin PS, Gelmann EP, Robert-Guroff M, Richardson E, Kalyanaraman VS, Mann D, Sidhu GD, Stahl RE, Zolla-Pazner S, et al. Isolation of human T-cell leukemia virus in acquired immune deficiency syndrome (AIDS). Science. 1983 May 20;220(4599):865–867. [PubMed]
  • Lane HC, Fauci AS. Immunologic abnormalities in the acquired immunodeficiency syndrome. Annu Rev Immunol. 1985;3:477–500. [PubMed]
  • Koff WC, Hoth DF. Development and testing of AIDS vaccines. Science. 1988 Jul 22;241(4864):426–432. [PubMed]
  • Barnes DM. Grim projections for AIDS epidemic. Science. 1986 Jun 27;232(4758):1589–1590. [PubMed]
  • Sprecher S, Soumenkoff G, Puissant F, Degueldre M. Vertical transmission of HIV in 15-week fetus. Lancet. 1986 Aug 2;2(8501):288–289. [PubMed]
  • Jovaisas E, Koch MA, Schäfer A, Stauber M, Löwenthal D. LAV/HTLV-III in 20-week fetus. Lancet. 1985 Nov 16;2(8464):1129–1129. [PubMed]
  • Cowan MJ, Hellmann D, Chudwin D, Wara DW, Chang RS, Ammann AJ. Maternal transmission of acquired immune deficiency syndrome. Pediatrics. 1984 Mar;73(3):382–386. [PubMed]
  • Ziegler JB, Cooper DA, Johnson RO, Gold J. Postnatal transmission of AIDS-associated retrovirus from mother to infant. Lancet. 1985 Apr 20;1(8434):896–898. [PubMed]
  • Pizzo PA, Eddy J, Faloon J. Acquired immune deficiency syndrome in children. Current problems and therapeutic considerations. Am J Med. 1988 Aug 29;85(2A):195–202. [PubMed]
  • Lewis SH, Reynolds-Kohler C, Fox HE, Nelson JA. HIV-1 in trophoblastic and villous Hofbauer cells, and haematological precursors in eight-week fetuses. Lancet. 1990 Mar 10;335(8689):565–568. [PubMed]
  • Broliden PA, Moschese V, Ljunggren K, Rosen J, Fundaro C, Plebani A, Jondal M, Rossi P, Wahren B. Diagnostic implication of specific immunoglobulin G patterns of children born to HIV-infected mothers. AIDS. 1989 Sep;3(9):577–582. [PubMed]
  • Rossi P, Moschese V, Broliden PA, Fundaró C, Quinti I, Plebani A, Giaquinto C, Tovo PA, Ljunggren K, Rosen J, et al. Presence of maternal antibodies to human immunodeficiency virus 1 envelope glycoprotein gp120 epitopes correlates with the uninfected status of children born to seropositive mothers. Proc Natl Acad Sci U S A. 1989 Oct;86(20):8055–8058. [PubMed]
  • Goedert JJ, Mendez H, Drummond JE, Robert-Guroff M, Minkoff HL, Holman S, Stevens R, Rubinstein A, Blattner WA, Willoughby A, et al. Mother-to-infant transmission of human immunodeficiency virus type 1: association with prematurity or low anti-gp120. Lancet. 1989 Dec 9;2(8676):1351–1354. [PubMed]
  • Devash Y, Calvelli TA, Wood DG, Reagan KJ, Rubinstein A. Vertical transmission of human immunodeficiency virus is correlated with the absence of high-affinity/avidity maternal antibodies to the gp120 principal neutralizing domain. Proc Natl Acad Sci U S A. 1990 May;87(9):3445–3449. [PubMed]
  • Auger I, Thomas P, De Gruttola V, Morse D, Moore D, Williams R, Truman B, Lawrence CE. Incubation periods for paediatric AIDS patients. Nature. 1988 Dec 8;336(6199):575–577. [PubMed]
  • Update: serologic testing for antibody to human immunodeficiency virus. MMWR Morb Mortal Wkly Rep. 1988 Jan 8;36(52):833–845. [PubMed]
  • Classification system for human immunodeficiency virus (HIV) infection in children under 13 years of age. MMWR Morb Mortal Wkly Rep. 1987 Apr 24;36(15):225–236. [PubMed]
  • Romano C, Williams WV, Fischberg DJ, Cocero N, Weiner DB, Greene MI, Molinoff PB. Subtype-selective immunoprecipitation of the beta 2-adrenergic receptor. J Neurochem. 1989 Aug;53(2):362–369. [PubMed]
  • Engvall E. Enzyme immunoassay ELISA and EMIT. Methods Enzymol. 1980;70(A):419–439. [PubMed]
  • Pierce SK, Klinman NR. Allogeneic carrier-specific enhancement of hapten-specific secondary B-cell responses. J Exp Med. 1976 Nov 2;144(5):1254–1262. [PMC free article] [PubMed]
  • Williams WV, Guy HR, Rubin DH, Robey F, Myers JN, Kieber-Emmons T, Weiner DB, Greene MI. Sequences of the cell-attachment sites of reovirus type 3 and its anti-idiotypic/antireceptor antibody: modeling of their three-dimensional structures. Proc Natl Acad Sci U S A. 1988 Sep;85(17):6488–6492. [PubMed]
  • Bolognesi DP. HIV antibodies and vaccine design. AIDS. 1989;3 (Suppl 1):S111–S118. [PubMed]
  • Parekh BS, Shaffer N, Pau CP, Abrams E, Thomas P, Pollack H, Bamji M, Kaul A, Schochetman G, Rogers M, et al. Lack of correlation between maternal antibodies to V3 loop peptides of gp120 and perinatal HIV-1 transmission. The NYC Perinatal HIV Transmission Collaborative Study. AIDS. 1991 Oct;5(10):1179–1184. [PubMed]
  • Chanh TC, Dreesman GR, Kanda P, Linette GP, Sparrow JT, Ho DD, Kennedy RC. Induction of anti-HIV neutralizing antibodies by synthetic peptides. EMBO J. 1986 Nov;5(11):3065–3071. [PubMed]
  • Dalgleish AG, Chanh TC, Kennedy RC, Kanda P, Clapham PR, Weiss RA. Neutralization of diverse HIV-1 strains by monoclonal antibodies raised against a gp41 synthetic peptide. Virology. 1988 Jul;165(1):209–215. [PubMed]
  • Thomas EK, Weber JN, McClure J, Clapham PR, Singhal MC, Shriver MK, Weiss RA. Neutralizing monoclonal antibodies to the AIDS virus. AIDS. 1988 Feb;2(1):25–29. [PubMed]
  • Weber JN, Clapham PR, Weiss RA, Parker D, Roberts C, Duncan J, Weller I, Carne C, Tedder RS, Pinching AJ, et al. Human immunodeficiency virus infection in two cohorts of homosexual men: neutralising sera and association of anti-gag antibody with prognosis. Lancet. 1987 Jan 17;1(8525):119–122. [PubMed]
  • Sawyer LA, Katzenstein DA, Hendry RM, Boone EJ, Vujcic LK, Williams CC, Zeger SL, Saah AJ, Rinaldo CR, Jr, Phair JP, et al. Possible beneficial effects of neutralizing antibodies and antibody-dependent, cell-mediated cytotoxicity in human immunodeficiency virus infection. AIDS Res Hum Retroviruses. 1990 Mar;6(3):341–356. [PubMed]
  • Vujcic LK, Shepp DH, Klutch M, Wells MA, Hendry RM, Wittek AE, Krilov L, Quinnan GV., Jr Use of a sensitive neutralization assay to measure the prevalence of antibodies to the human immunodeficiency virus. J Infect Dis. 1988 May;157(5):1047–1050. [PubMed]
  • Wendler I, Bienzle U, Hunsmann G. Neutralizing antibodies and the course of HIV-induced disease. AIDS Res Hum Retroviruses. 1987 Summer;3(2):157–163. [PubMed]
  • Faulkner-Valle GP, De Rossi A, Dalla Gassa O, Chieco-Bianchi L. LAV/HTLV-III neutralizing antibodies in the sera of patients with AIDS, lymphadenopathy syndrome and asymptomatic seropositive individuals. Tumori. 1986 Jun 30;72(3):219–224. [PubMed]
  • Ljunggren K, Moschese V, Broliden PA, Giaquinto C, Quinti I, Fenyö EM, Wahren B, Rossi P, Jondal M. Antibodies mediating cellular cytotoxicity and neutralization correlate with a better clinical stage in children born to human immunodeficiency virus-infected mothers. J Infect Dis. 1990 Feb;161(2):198–202. [PubMed]

Articles from The Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation